Abstract
BackgroundCollagenase Clostridium histolyticum (CCH), recently approved in Europe is an efficacious, minimally invasive, and well tolerated treatment for Dupuytren’s contracture (DC).ObjectivesTo report efficacy/safety and recurrence rates 3 years after CCH...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
